Cidara Therapeutics, Inc., a San Diego, CA-based biopharmaceutical company, completed a $32m Series A financing.
The round was led by 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners and also included select institutional cross over investors. In connection with the financing, Steve Elms, Patrick Heron and former Trius board member Nina Kjellson have also joined the Cidara board.
The company will use the funds to advance candidates from its Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
Cidara was co-founded by COO Kevin Forrest, Ph.D. (of 5AM Ventures), CSO Kevin Judice, Ph.D, founder and former chief executive officer of Achaogen Pharmaceuticals, and H. Shaw Warren, M.D., of Harvard University and Massachusetts General Hospital (member of the scientific advisory board) and led by president and chief executive officer Jeffrey Stein, Ph.D., chief development officer Ken Bartizal, Ph.D., and chief medical officer Dirk Thye, M.D.